Sodium–glucose co-transporter-2 inhibitors for hospitalised patients with COVID-19: a prospective meta-analysis of randomised trials
Pooled result · All-cause mortalityResult — go to the resultSummary OR 0.93 95% CI 0.79–1.08Authors' conclusion
Although administration of SGLT2 inhibitor was safe, we found no clear evidence that adding SGLT2 inhibitor therapy improved outcomes in patients hospitalised with COVID-19 compared with usual care or placebo. These data do not support the use of SGLT2 inhibitors as standard treatment in adults hospitalised for COVID-19.
Study context
- Population
- Adults hospitalised with COVID-19; 39% women, 25% T2D at randomisation
- Participants
- 6,096 adults3 randomised control trials (RCTs)
- Comparison
- Oral SGLT2 inhibitors vs usual care or placebo
- SGLT2 inhibitorn = 3,025
- Usual care or placebon = 3,071reference
- Outcome
- All-cause mortality
- Follow-up
- 28 days
Methodological detailsinverse variance weighted meta-analysis, prespecified summary outcome data, Risk of bias assessed with Cochrane tool: low
- Inverse variance weighted meta-analysis
- Prespecified summary outcome data
- Risk of bias assessed with Cochrane tool: low
Pooled result
As reported in the abstract
Summary OR
0.93
95% CI 0.79–1.08
P = 0.33
Events by group
SGLT2 inhibitor
351
events
Usual care or placebo
382
events
SGLT2 inhibitorvs Usual care or placebo
summary OR 0.93 (95% CI 0.79–1.08); P = 0.33
Safety
Events
| Outcome | SGLT2 inhibitor | Usual care or placebo |
|---|---|---|
| Ketoacidosis (primary safety outcome) · 28 days | 7 | 2 |
Original publication
Sodium–glucose co-transporter-2 inhibitors for hospitalised patients with COVID-19: a prospective meta-analysis of randomised trials. Lancet Diabetes Endocrinol. Published 6 September 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →